A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ATMOSPHERE)
Amy Pikalek
UNITY
A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema
PEP
Patient Experience and Preference (PEP) Study in nAMD and DME
Teaming Up for Gene Therapy
*This article originally appeared in the McPherson Eye Research Institute Summer 2021 InSights Newsletter Millions of Americans currently battle inherited visual disorders, armed with very few therapeutic options. Recent advances in genome editing, which many believe …
MAC TEL
Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (Mac Tel)
BIM2
To identify whether genetic variation or polymorphism in genes that impact angiogenesis can be identified as biomarkers for responsiveness to anti-VEGF therapy in patients with neovascular age-related macular degeneration.
GENETIC EYE DISORDERS
To identify the gene or genes responsible for developmental causes of blindness in the world, and to establish a Pediatric Ophthalmic Genetics and Research Program at the University of Wisconsin–Madison.
XOLARIS
To gain a better understanding of disease progression over time in male subjects with X-linked retinitis pigmentosa (XLRP).
CHM SURVEY TRIAL
Choroideremia (CHM) Health Outcomes